Q1 2026 Aurobindo Pharma Ltd Earnings Call Transcript
Key Points
- Aurobindo Pharma Ltd (BOM:524804) reported a 4% year-on-year increase in consolidated revenues, reaching INR7,868 crore, driven by strong performance in European and growth market operations.
- The company achieved a stable EBITDA margin of 20.4%, despite a lower contribution from G Revlimid.
- European business continued its strong trajectory with a 9% year-on-year revenue growth, and the company expects to cross EUR1 billion in annual revenues for the region by the end of FY26.
- The company successfully resumed operations at its PenG manufacturing plant, with encouraging yields and confidence in sustaining momentum.
- Aurobindo Pharma Ltd (BOM:524804) launched 15 new products in the US this quarter, filed 4 ANDAs, and received 14 approvals, indicating robust product pipeline development.
- US revenues experienced a year-on-year decline of 4% to $408 million, primarily due to a significant reduction in the transient product sale G Revlimid.
- API business revenues declined by 16% year-on-year to INR916 crore, impacted by geopolitical challenges, business mix, and pricing pressures.
- The company faced intensified pricing pressure on Revlimid, with most settlement quantities already sold, limiting future revenue opportunities from this product.
- Operational losses were incurred in various plants, with PenG being the biggest loss last year, although improvements are expected in the coming quarters.
- The company is facing challenges in the US market due to destocking effects and seasonal dynamics, impacting overall sales performance.
Thank you, Vandit. Good morning, everyone. Welcome to our first-quarter FY26 earnings call. I'm Varun Mali from the Investor Relations and the Corporate Communications team. We hope you have received the Q1 FY26 financials and the press release that was sent out yesterday.
These are also available on our website. I would now like to introduce you to our senior management on the call today. Dr. Satakarni Makkapati, CEO, Aurobindo Biosimilars, Vaccines and Peptides Businesses and Director, Aurobindo Pharma Limited; Mr. Yugandhar Puvvala, CEO, Eugia Pharma Specialties Limited; Mr. Swami Iyer, CEO, Aurobindo Pharma, USA; Mr. V. Muralidharan, CEO, Europe Formulations Business; Mr. S. Subramanian, CFO, Aurobindo Pharma Limited.
We will begin the call with the summary highlights from the management followed by an interactive Q&A session. Please note that some of the matters we will discuss today are forward-looking, including and without limitations, statements relating to the implementation of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
